{"id":"sigmart-nicorandil","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL284906","moleculeType":"Small molecule","molecularWeight":"211.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicorandil is a potassium channel opener with dual mechanism of action: it activates ATP-sensitive potassium channels in coronary and peripheral blood vessels, causing vasodilation and reducing myocardial oxygen demand. Additionally, it possesses nitrate-like properties that contribute to its vasodilatory effects. This combination reduces both preload and afterload on the heart, improving coronary blood flow and myocardial perfusion.","oneSentence":"Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:54.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Angina pectoris (chronic stable angina and angina prophylaxis)"},{"name":"Ischemic heart disease"}]},"trialDetails":[{"nctId":"NCT05682118","phase":"NA","title":"Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-07-31","conditions":"Ischemic Heart Disease","enrollment":226},{"nctId":"NCT01475123","phase":"PHASE4","title":"Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kumamoto University","startDate":"2008-06","conditions":"Coronary Artery Disease, End Stage Renal Disease","enrollment":268},{"nctId":"NCT04631536","phase":"PHASE3","title":"Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","status":"UNKNOWN","sponsor":"Lebanese American University Medical Center","startDate":"2021-01-10","conditions":"Covid19","enrollment":42},{"nctId":"NCT02809456","phase":"PHASE2","title":"Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2016-07","conditions":"Radiation Pneumonitis","enrollment":50},{"nctId":"NCT02328521","phase":"PHASE4","title":"Efficacy Study of Nicorandil on Neointima","status":"UNKNOWN","sponsor":"Zhang Ying Qian","startDate":"2014-12","conditions":"Angina, Unstable, Diabetes Mellitus","enrollment":48},{"nctId":"NCT01185015","phase":"PHASE4","title":"A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization","status":"WITHDRAWN","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-01","conditions":"Angina Pectoris","enrollment":""},{"nctId":"NCT01103336","phase":"PHASE4","title":"Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Chronic Renal Failure","enrollment":173}],"_emaApprovals":[],"_faersSignals":[{"count":19,"reaction":"CONDITION AGGRAVATED"},{"count":18,"reaction":"CARDIAC FAILURE"},{"count":12,"reaction":"BLOOD PRESSURE DECREASED"},{"count":11,"reaction":"ANAEMIA"},{"count":11,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":11,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":11,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":10,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":10,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":9,"reaction":"BLOOD CREATINE PHOSPHOKINASE INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sigmart®"],"phase":"marketed","status":"active","brandName":"Sigmart (nicorandil)","genericName":"Sigmart (nicorandil)","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload. Used for Angina pectoris (chronic stable angina and angina prophylaxis), Ischemic heart disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}